Antibodies against Plasmodium falciparum surface protein, Pfs25, are known to block parasite development in the mosquito vector. However, in initial clinical trials the limited immunogenicity of recombinant Pfs25 protein-in-adjuvant vaccines has been a challenge. In this study, Ad5-based vaccine vectors were developed to direct the Pfs25-specific antibody response to relevant, transmission-blocking epitopes.

Author: McGuire KA, Miura K, Wiethoff CM, Williamson KC
Publication date: June 2017
Source: Malaria Journal